Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that recent setbacks in the development of promising new drugs for congestive heart failure (CHF) mean continued high mortality and morbidity rates for patients with the disease. Drugs from Bristol-Myers Squibb, Roche and Immunex designed for the treatment of CHF have all hit major roadblocks.

(Photo: )

"The market for drugs for congestive heart failure will feel the affects of disappointing results from once promising new compounds," said John Earl, PH.D., director at Decision Resources. "The FDA refused to approve Bristol- Myers Squibb's Vanlev (omapatrilat) for the treatment of resistant hypertension and both Roche/Acetlion/Genetech's endothelin antagonist and Immunex's anti-tumor necrosis factor therapy were discontinued following poor Phase III trial results."

Disease Background-Congestive Heart Failure

Chronic congestive heart failure is a major public health problem associated with considerable mortality and morbidity rates. Both the incidence and prevalence of CHF nearly doubled with each decade of life over the age of 50, and in the United States, CHF is the most frequent cause of hospitalization in patients aged 65 or older. The annual costs for CHF in the United States are estimated to be between $21 billion and $40 billion. In Europe, CHF accounts for about 2% of total health care expenditures, and worldwide, CHF is the fastest-growing cardiovascular disorder.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Congestive Heart Failure is a Cardium report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

Make Your Opinion Count - Click Here

Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Psoriasis Drug Market to Reach $3.9 Billion in 2011

View Now